Clinical Trial Update: A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G [Phase 2]

View source ↗

Summary

Phase 2 trial of ADX-097 for IgA nephropathy, lupus nephritis, and C3 glomerulopathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy
• Iga Nephropathy
• Lupus Nephritis

Drugs mentioned

• ADX-097

Snippet

Sponsor: Q32 Bio Inc. | Conditions: IgA Nephropathy, Lupus Nephritis (LN) | Phase 2 | Status: WITHDRAWN